James Brumley

James Brumley

James Brumley is a reformed stock broker and former Director of Research for an options-focused newsletter. He’s now primarily a freelance writer, tapping more than a decade’s worth of broad experience to help investors get more out of the market.

With a background in technical analysis as well as fundamental analysis, James writes with a multifaceted philosophy that combines the importance of company performance with the power of stock-trade timing. His commentary is as apt to focus on a chart as it is earnings, as he believes this dual approach is the only way an investor has a shot at consistently beating the market.

James’ work has appeared at several websites, including Street Authority, Motley Fool, Kapitall and Investopedia. When not writing as a journalist, James works on his book explaining his multipronged approach to investing.

Recent Articles

Why Wells Fargo & Co Stock Can’t Catch a Break

Plenty of traders are tempted to step into Wells Fargo stock on Monday's selloff, but WFC is just too much of an unknown to bother with at this time.

The Future of Merck & Co., Inc. Stock Is With Keytruda

Merck & Co's cancer drug, Keytruda, saw explosive growth this quarter, making MRK stock a tough name to handicap right now.

There’s a Glimmer of Hope for Snap Inc Stock

SNAP stock is still too risky to trade in front of earnings, but believers in the potential of Snapchat can be encouraged by the new business-minded moves.

3 Things to Know About Walt Disney Co Stock Before Tuesday’s Close

You may not want to step into DIS stock until after Walt Disney makes it clear how, or if, it's going to rev up its television arm.

Will Altria Group Inc Shareholders See The Company Go Up In Smoke?

MO stock may remain a dividend champ for the foreseeable future, but Altria Group isn't a name you can plan on owning indefinitely.